New antibody shows promise against tough cancers in early trial
NCT ID NCT04556253
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a drug called AK104, which helps the immune system attack cancer cells, in people with specific types of stomach or colorectal cancer. Participants receive the drug before and after surgery to see if it can completely eliminate the tumor. The trial involves 47 patients and focuses on safety and how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK104 (a bispecific antibody targeting PD-1 and CTLA-4)
- What this could lead to
- If successful, this could lead to a new treatment option that improves the chance of eliminating tumors before and after surgery for certain gastric and colorectal cancers.
- What could go wrong
- This is an early-phase trial with only 47 participants, so results may not apply to everyone. The treatment may cause side effects from immune system activation, and it's not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT LOCALLY ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China